Literature DB >> 16506079

A dose-finding study of duloxetine based on serotonin transporter occupancy.

Akihiro Takano1, Kazutoshi Suzuki, Jun Kosaka, Miho Ota, Shoko Nozaki, Yoko Ikoma, Shuji Tanada, Tetsuya Suhara.   

Abstract

RATIONALE: Positron emission tomography (PET) has been utilized for determining the dosage of antipsychotic drugs. To evaluate the dosage of antidepressants such as selective serotonin reuptake inhibitors, serotonin transporter occupancy (5-HTT) is also a useful index.
OBJECTIVES: We investigated the degree of 5-HTT occupancy with different doses of the antidepressant duloxetine and the time-course of 5-HTT occupancy using PET.
METHODS: PET scans with [11C]DASB were performed before and after a single administration of duloxetine (5-60 mg), and three consecutive scans were performed after a single dose or repeated doses of 60 mg of duloxetine.
RESULTS: 5-HTT occupancies by duloxetine were increased by 35.3 to 86.5% with dose and plasma concentration increments. The ED50 value of 5-HTT occupancy was 7.9 mg for dose and 3.7 ng/ml for plasma concentration. In the time-course of 5-HTT occupancy, mean occupancies were 81.8% at 6 h, 71.9% at 25 h, and 44.9% at 53 h after a single administration, and 84.3% at 6 h, 71.9% at 49 h, and 47.1% at 78 h after repeated administrations.
CONCLUSIONS: Based on 5-HTT occupancy, 40 mg and more of duloxetine was needed to attain 80% occupancy, and 60 mg of duloxetine could maintain a high level of 5-HTT occupancy with a once-a-day administration schedule.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16506079     DOI: 10.1007/s00213-005-0304-0

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  28 in total

1.  Onset of action for duloxetine 60 mg once daily: double-blind, placebo-controlled studies.

Authors:  Stephen K Brannan; Craig H Mallinckrodt; Michael J Detke; John G Watkin; Gary D Tollefson
Journal:  J Psychiatr Res       Date:  2005-03       Impact factor: 4.791

2.  Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain.

Authors:  Masanori Ichise; Jeih-San Liow; Jian-Qiang Lu; Akihiro Takano; Kendra Model; Hiroshi Toyama; Tetsuya Suhara; Kazutoshi Suzuki; Robert B Innis; Richard E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2003-09       Impact factor: 6.200

3.  Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors.

Authors:  F P Bymaster; L J Dreshfield-Ahmad; P G Threlkeld; J L Shaw; L Thompson; D L Nelson; S K Hemrick-Luecke; D T Wong
Journal:  Neuropsychopharmacology       Date:  2001-12       Impact factor: 7.853

4.  Duloxetine (LY 248686): an inhibitor of serotonin and noradrenaline uptake and an antidepressant drug candidate.

Authors:  D T Wong
Journal:  Expert Opin Investig Drugs       Date:  1998-10       Impact factor: 6.206

5.  Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study.

Authors:  J H Meyer; A A Wilson; N Ginovart; V Goulding; D Hussey; K Hood; S Houle
Journal:  Am J Psychiatry       Date:  2001-11       Impact factor: 18.112

6.  Novel radiotracers for imaging the serotonin transporter by positron emission tomography: synthesis, radiosynthesis, and in vitro and ex vivo evaluation of (11)C-labeled 2-(phenylthio)araalkylamines.

Authors:  A A Wilson; N Ginovart; M Schmidt; J H Meyer; P G Threlkeld; S Houle
Journal:  J Med Chem       Date:  2000-08-10       Impact factor: 7.446

7.  Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.

Authors:  Michael J Detke; Curtis G Wiltse; Craig H Mallinckrodt; Robert K McNamara; Mark A Demitrack; Istvan Bitter
Journal:  Eur Neuropsychopharmacol       Date:  2004-12       Impact factor: 4.600

8.  Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects.

Authors:  J E Turcotte; G Debonnel; C de Montigny; C Hébert; P Blier
Journal:  Neuropsychopharmacology       Date:  2001-05       Impact factor: 7.853

9.  Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study.

Authors:  Jeffrey H Meyer; Alan A Wilson; Sandra Sagrati; Doug Hussey; Anna Carella; William Z Potter; Nathalie Ginovart; Edgar P Spencer; Andy Cheok; Sylvain Houle
Journal:  Am J Psychiatry       Date:  2004-05       Impact factor: 18.112

10.  Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression.

Authors:  Michael J Detke; Yili Lu; David J Goldstein; Robert K McNamara; Mark A Demitrack
Journal:  J Psychiatr Res       Date:  2002 Nov-Dec       Impact factor: 4.791

View more
  28 in total

1.  Prediction of repeat-dose occupancy from single-dose data: characterisation of the relationship between plasma pharmacokinetics and brain target occupancy.

Authors:  Sergio Abanades; Jasper van der Aart; Julien A R Barletta; Carmine Marzano; Graham E Searle; Cristian A Salinas; Javaad J Ahmad; Richard R Reiley; Sabina Pampols-Maso; Stefano Zamuner; Vincent J Cunningham; Eugenii A Rabiner; Marc A Laruelle; Roger N Gunn
Journal:  J Cereb Blood Flow Metab       Date:  2010-10-13       Impact factor: 6.200

2.  Synthesis, radiosynthesis, and biological evaluation of fluorine-18-labeled 2beta-carbo(fluoroalkoxy)-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography.

Authors:  Jeffrey S Stehouwer; Nachwa Jarkas; Fanxing Zeng; Ronald J Voll; Larry Williams; Vernon M Camp; Eugene J Malveaux; John R Votaw; Leonard Howell; Michael J Owens; Mark M Goodman
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

3.  Evaluation of safety and tolerability, pharmacokinetics, and pharmacodynamics of BMS-820836 in healthy subjects: a placebo-controlled, ascending single-dose study.

Authors:  Robert Risinger; Zubin Bhagwagar; Feng Luo; Matthew Cahir; Laura Miler; Anisha E Mendonza; Jeffrey H Meyer; Ming Zheng; Wendy Hayes
Journal:  Psychopharmacology (Berl)       Date:  2013-12-15       Impact factor: 4.530

4.  Fluorine-18 Radiolabeled PET Tracers for Imaging Monoamine Transporters: Dopamine, Serotonin, and Norepinephrine.

Authors:  Jeffrey S Stehouwer; Mark M Goodman
Journal:  PET Clin       Date:  2009-01

5.  Cerebral serotonin transporter measurements with [11C]DASB: A review on acquisition and preprocessing across 21 PET centres.

Authors:  Martin Nørgaard; Melanie Ganz; Claus Svarer; Ling Feng; Masanori Ichise; Rupert Lanzenberger; Mark Lubberink; Ramin V Parsey; Marios Politis; Eugenii A Rabiner; Mark Slifstein; Vesna Sossi; Tetsuya Suhara; Peter S Talbot; Federico Turkheimer; Stephen C Strother; Gitte M Knudsen
Journal:  J Cereb Blood Flow Metab       Date:  2018-04-13       Impact factor: 6.200

Review 6.  Duloxetine: clinical pharmacokinetics and drug interactions.

Authors:  Mary Pat Knadler; Evelyn Lobo; Jill Chappell; Richard Bergstrom
Journal:  Clin Pharmacokinet       Date:  2011-05       Impact factor: 6.447

7.  SERT and NET occupancy by venlafaxine and milnacipran in nonhuman primates: a PET study.

Authors:  Akihiro Takano; Christer Halldin; Lars Farde
Journal:  Psychopharmacology (Berl)       Date:  2012-10-23       Impact factor: 4.530

Review 8.  Duloxetine: in patients with fibromyalgia.

Authors:  Monique P Curran
Journal:  Drugs       Date:  2009-06-18       Impact factor: 9.546

9.  Imaging serotonergic transmission with [11C]DASB-PET in depressed and non-depressed patients infected with HIV.

Authors:  Dima A Hammoud; Christopher J Endres; Edward Hammond; Ovsev Uzuner; Amanda Brown; Avindra Nath; Adam I Kaplin; Martin G Pomper
Journal:  Neuroimage       Date:  2009-10-21       Impact factor: 6.556

Review 10.  Duloxetine: a review of its use in the treatment of generalized anxiety disorder.

Authors:  Natalie J Carter; Paul L McCormack
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.